<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1999
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to_______
Commission File No. 0-24425
KING PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
TENNESSEE 54-1684963
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
501 FIFTH STREET 37620
BRISTOL, TN
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (423) 989-8000
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No
---- ----
<TABLE>
<CAPTION>
CLASS OUTSTANDING SHARES AT MARCH 31, 1999
----- ------------------------------------
<S> <C>
Common 32,105,050
</TABLE>
<PAGE> 2
KING PHARMACEUTICALS, INC.
INDEX
PART I - FINANCIAL INFORMATION
Item 1: Financial Statements (unaudited)
<TABLE>
<S> <C>
Condensed Consolidated Balance Sheets as of March 31, 1999
and December 31, 1998.................................................... 2
Condensed Consolidated Statements of Operations for the three months
ended March 31, 1999 and 1998............................................ 4
Condensed Consolidated Statements of Cash Flows for the three months
ended March 31, 1999 and 1998............................................ 6
Notes to Condensed Consolidated Financial Statements..................... 7
Item 2: Management's Discussion and Analysis of Financial Condition and
Results of Operations .......................................... 14
PART II - OTHER INFORMATION
Item 1: Legal Proceedings............................................... 20
Item 2: Changes in Securities and Use of Proceeds ...................... 20
Item 6: Exhibits and Reports on Form 8-K................................ 21
SIGNATURES............................................................... 22
</TABLE>
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
KING PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1999 1998
---------------------------
(Unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 2,484 $ 1,159
Accounts receivable, net 43,263 39,666
Inventory 36,553 26,556
Deferred income taxes 5,717 6,675
Prepaid expenses and other assets 2,548 1,554
--------- ---------
Total current assets 90,565 75,610
--------- ---------
Property, plant and equipment, net 94,313 93,981
Intangible assets, net 475,650 480,583
Other assets 21,554 17,997
--------- ---------
Total assets $ 682,082 $ 668,171
========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt:
Term loans $ 9,124 $ 10,250
Other 1,374 3,060
Accounts payable 12,526 12,594
Accrued expenses 19,561 15,095
Income taxes payable 4,008 3,524
--------- ---------
Total current liabilities 46,593 44,523
--------- ---------
Long-term debt:
Revolving credit facility 1,826 19,000
Term loans 363,915 414,750
Senior subordinated notes 150,000 --
Senior subordinated seller notes -- 75,000
Other 5,547 5,736
Deferred income taxes 6,768 7,726
--------- ---------
Total liabilities 574,649 566,735
--------- ---------
Shareholders' equity:
Common shares, no par value, 150,000,000 shares
authorized, 32,105,054 and 28,000,000 shares issued
and outstanding, respectively 66,576 66,572
Retained earnings 41,453 35,460
Due from related party (596) (596)
--------- ---------
Total shareholders' equity 107,433 101,436
--------- ---------
Total liabilities and shareholders' equity $ 682,082 $ 668,171
========= =========
</TABLE>
See accompanying notes.
2
<PAGE> 4
KING PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share data)
<TABLE>
<CAPTION>
FOR THE THREE MONTHS
ENDED MARCH 31,
1999 1998
--------- ----------
(Unaudited)
<S> <C> <C>
REVENUES:
Net sales $ 60,002 $ 22,319
Development revenues -- 2,658
-------- --------
Total revenues 60,002 24,977
-------- --------
OPERATING COSTS AND EXPENSES:
Cost of sales 15,810 7,364
Selling, general and administrative 14,282 6,832
Depreciation and amortization 6,251 1,091
-------- --------
Total operating costs and expenses 36,343 15,287
-------- --------
OPERATING INCOME 23,659 9,690
OTHER (EXPENSES) INCOME:
Interest expense (12,719) (2,703)
Interest income 46 24
Other income (expense) (88) --
-------- --------
Total other (expenses) (12,761) (2,679)
-------- --------
INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY ITEM 10,898 7,011
Income tax expense 4,200 2,650
-------- --------
INCOME BEFORE EXTRAORDINARY 6,698 4,361
ITEM
Extraordinary item, net of income taxes (705) (286)
-------- --------
NET INCOME $ 5,993 $ 4,075
======== ========
Basic and diluted income per common share:
Income before extraordinary item $ 0.21 $ 0.16
Extraordinary item (0.02) (.01)
-------- --------
Net income $ 0.19 $ 0.15
======== ========
</TABLE>
See accompanying notes.
3
<PAGE> 5
KING PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, except share data)
<TABLE>
<CAPTION>
FOR THE THREE MONTHS
ENDED MARCH 31,
1999 1998
--------- ---------
(Unaudited)
<S> <C> <C>
Net cash provided by (used in) operating activities $ 5,500 $ (5,364)
--------- ---------
Cash flows from investing activities:
Purchases of property and equipment (1,718) (73,642)
Purchases of intangible assets -- (51,559)
--------- ---------
Net cash used in investing activities (1,718) (125,201)
--------- ---------
Cash flows from financing activities:
Proceeds from revolving line of credit 5,000 17,139
Payments on revolving line of credit (22,174) (13,291)
Payments on short-term debt -- (118)
Proceeds from long-term debt and capital lease obligations -- 175,000
Payments on long-term debt and capital lease obligations (58,836) (40,296)
Due from affiliate -- 3
Initial public offering costs -- (602)
Repayment of senior subordinated seller notes (75,000) --
Proceeds from senior subordinated notes 150,000 --
Debt issuance costs (6,451) (7,335)
Proceeds from exercise of stock options 4 --
--------- ---------
Net cash (used in) provided by financing activities (2,457) 130,500
--------- ---------
Increase (decrease) in cash 1,325 (65)
Cash and cash equivalents, beginning of the period 1,159 69
--------- ---------
Cash and cash equivalents, end of the period $ 2,484 $ 4
========= =========
</TABLE>
See accompanying notes.
4
<PAGE> 6
KING PHARMACEUTICALS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(IN THOUSANDS, EXCEPT SHARE DATA)
NOTE 1. GENERAL
The accompanying unaudited interim condensed consolidated financial
statements of King Pharmaceuticals, Inc. (the "Company") have been prepared by
us in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation
S-X, and accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting of items
of a normal recurring nature) considered necessary for a fair presentation have
been included. Operating results for the three months ended March 31, 1999 are
not necessarily indicative of the results that may be expected for the year
ended December 31, 1999. The interim financial statements should be read in
conjunction with the financial statements and notes thereto included in the
Company's latest Annual Report on Form 10-K.
NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS
In 1998, the Financial Accounting Standards Board issued SFAS No. 133,
Accounting for Derivative Instruments and Hedging Activities. SFAS No. 133 is
effective for all fiscal quarters of all fiscal years beginning after June 15,
1999. SFAS No. 133 requires that all derivative instruments be recorded on the
balance sheet at their fair value. Changes in the fair value of derivatives are
recorded each period in current earnings or other comprehensive income,
depending on whether a derivative is designated as part of a hedge transaction
and, if it is, the type of hedge transaction. Management is evaluating the
provisions of SFAS No. 133, but management has not yet determined the impact, if
any of its adoption.
NOTE 3. INCOME PER SHARE
The following table sets forth a reconciliation of the numerators and
denominators in computing income per share:
<TABLE>
<CAPTION>
For the Three Months
Ended March 31,
1999 1998
----------- -----------
(Unaudited)
<S> <C> <C>
Net income $ 5,993 $ 4,075
=========== ===========
Weighted average basic shares outstanding 32,104,793 28,000,000
Effect of dilutive stock options 123,401 --
----------- -----------
Dilutive shares outstanding 32,228,194 28,000,000
=========== ===========
Basic and diluted net income per share $ 0.19 $ 0.15
=========== ===========
</TABLE>
NOTE 4. INVENTORY
Inventory consists of the following:
<TABLE>
<CAPTION>
March 31, December 31,
1999 1998
------------ -------------
(Unaudited)
<S> <C> <C>
Finished goods................................... $16,303 $13,772
Work-in-process.................................. 11,777 5,386
Raw materials.................................... 8,473 7,398
------- -------
$36,553 $26,556
======= =======
</TABLE>
5
<PAGE> 7
NOTE 5. PROPERTY, PLANT AND EQUIPMENT:
Property, plant and equipment consists of the following:
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1999 1998
---------- ------------
(Unaudited)
<S> <C> <C>
Land.............................................. $ 3,974 $ 3,949
Building and improvements......................... 56,006 55,990
Machinery and equipment........................... 35,408 35,235
Construction in progress.......................... 7,534 6,106
-------- ---------
102,922 101,280
Less accumulated depreciation..................... (8,609) (7,299)
-------- ---------
$ 94,313 $ 93,981
======== =========
</TABLE>
NOTE 6. ACQUISITIONS/INTANGIBLE ASSETS
Intangible assets are as follows:
<TABLE>
<CAPTION>
March 31, December 31,
1999 1998
----------- -----------
(Unaudited)
<S> <C> <C>
Altace(R), Silvadene(R), AVC(TM) ................ $ 362,950 $ 362,950
Septra(R), Proloprim(R), Mantadil(R), Kemadrin(R) 15,425 15,425
Cortisporin(R) .................................. 23,694 23,694
Sterile Products ................................ 54,509 54,509
Neosporin(R) .................................... 5,876 5,876
Viroptic(R) ..................................... 5,229 5,229
Nucofed(R)/Quibron(R) ........................... 7,301 7,301
Polysporin(R) ................................... 3,783 3,783
Menest(R) ....................................... 5,000 5,000
Other ........................................... 3,377 3,377
--------- ---------
487,144 487,144
Less accumulated amortization ................... (11,494) (6,561)
--------- ---------
$ 475,650 $ 480,583
========= =========
</TABLE>
The following unaudited pro forma summary presents the financial information
as if certain of the Company's acquisitions had occurred on January 1, 1998.
These pro forma results have been prepared for comparative purposes and do not
purport to be indicative of what would have occurred had the acquisitions been
made on January 1, 1998, nor is it indicative of future results.
<TABLE>
<CAPTION>
For the three
months ended
--------------
March 31, 1998
--------------
<S> <C>
Total revenues ............................. $56,049
=======
Income before extraordinary item ........... $ 5,856
=======
Net income ................................. $ 5,856
=======
Diluted income per common share:
Net income before extraordinary item...... $ 0.21
=======
Net income ............................. $ 0.21
=======
</TABLE>
NOTE 7. CONTINGENCIES
Except as described below, the Company has not been a party to
significant litigation or other legal proceedings.
Many distributors, marketers and manufacturers of anorexigenic drugs
have been subject to claims relating to the use of these drugs. We are a
defendant in 67 lawsuits which claim damages for personal injury arising from
the Company's production of the anorexigenic drug, phentermine, under contract
for SmithKline Beecham Corporation ("SKB"). Generally, the lawsuits allege that
the defendants (1) misled users of the products with respect to the dangers
associated with them, (2) failed to adequately test the products, and (3) knew
or should have known about the negative effects of the drugs, and should have
informed the public about the risks of such negative effects. The actions
generally have been brought by individuals in their own right and have been
filed in various state and federal jurisdictions throughout the United States.
They seek, among other things, compensatory and punitive damages and/or court
supervised medical
6
<PAGE> 8
monitoring of persons who have ingested the product. The Company expects to be
named in additional lawsuits related to the production of this anorexigenic
drug.
While the Company cannot predict the outcome of these suits, management
believes that the claims against the Company are without merit and intend to
vigorously pursue all defenses available to the Company. The Company is being
indemnified in all of these suits by SKB for which the Company manufactured the
anorexigenic product, provided that neither the lawsuits nor the associated
liabilities are based upon the Company's independent negligence or intentional
acts, and intend to submit a claim for all unreimbursed costs to the Company's
product liability insurance carrier. However, in the event that SKB is unable to
satisfy or fulfill its obligations under the indemnity, the Company would have
to defend the lawsuit and be responsible for damages, if any, which are awarded
against the Company or for amounts in excess of the Company's product liability
coverage.
NOTE 8. LONG-TERM DEBT
On March 3, 1999, the Company issued $150,000 of 10 3/4% Senior
Subordinated Notes due 2009. Net proceeds of approximately $144,000 were used to
repay outstanding indebtedness under the Senior Credit Facility ($69,000) and
the Seller Note ($75,000). The debt is guaranteed by the Company's wholly-owned
subsidiaries Monarch Pharmaceuticals, Inc., Parkedale Pharmaceuticals, Inc. and
King Pharmaceuticals of Nevada, Inc. In addition, the Company increased its
borrowing capacity under its Revolving Credit Facility to $100,000. As of March
31, 1999, the Company has $98,174 of availability under the Revolving Credit
Facility.
As a result of the early retirement of the Senior Subordinated Seller
Notes transaction costs of $1,150 ($705, net of income tax) were written off as
an extraordinary loss on the early retirement of indebtedness.
On May 7, 1999, the Company's Registration Statement on Form S-4
relating to the offer to exchange all outstanding 10 3/4% Senior Subordinated
Notes due 2009 ($150,000 aggregate principal amount outstanding) for 10 3/4%
Senior Subordinated Notes due 2009 of King Pharmaceuticals, Inc was declared
effective by the Securities and Exchange Commission.
NOTE 9. SEGMENT INFORMATION
The Company primarily evaluates its segments based on gross profit.
Reportable segments were separately identified based on revenues, gross profit
and total assets.
The following represents selected information for the Company's
operating segments for the periods indicated:
7
<PAGE> 9
<TABLE>
<CAPTION>
For the Three Months Ended
March 31,
-----------------------
1999 1998
--------- ----------
(Unaudited)
<S> <C> <C>
TOTAL REVENUES:
Branded pharmaceuticals............................ $50,939 $ 17,570
Contract manufacturing............................. 13,665 5,405
All other.......................................... 1,000 2,889
Eliminations....................................... (5,602) (887)
-------- --------
Consolidated total revenues................... $ 60,002 $ 24,977
======== ========
GROSS PROFIT (LOSS):
Branded pharmaceuticals............................ $42,742 $ 15,204
Contract manufacturing............................. 794 (400)
All other.......................................... 656 2,809
------- --------
Consolidated gross profit..................... $44,192 $ 17,613
====== ========
</TABLE>
<TABLE>
<CAPTION>
As of As of
December 31, March 31,
1998 1999
-------- --------
(Unaudited)
<S> <C> <C>
TOTAL ASSETS:
Branded pharmaceuticals............................ $522,218 $526,194
Contract manufacturing............................. 144,614 152,944
All other.......................................... 1,735 3,617
Eliminations....................................... (396) (673)
-------- --------
Consolidated total assets..................... $668,171 $682,082
======== ========
</TABLE>
Capital expenditures of $8,099, $598 and $1,718 for the year ended
December 31, 1998 and the three months ended March 31, 1998 and 1999,
respectively, are substantially utilized for contract manufacturing purposes.
NOTE 10. GUARANTOR FINANCIAL STATEMENTS
The Company's wholly-owned subsidiaries Monarch Pharmaceuticals, Inc.,
Parkedale Pharmaceuticals, Inc., and King Pharmaceuticals of Nevada, Inc. (the
"Guarantor Subsidiaries") have guaranteed the Company's performance under the
$150,000 of 10 3/4% Senior Subordinated Notes due 2009 on a joint and several
basis. There are no restrictions under the Company's financing arrangements on
the ability of the Guarantor Subsidiaries to distribute funds to the Company in
the form of cash dividends, loans or advances. The following combined financial
data provides information regarding the financial position, results of
operations and cash flows of the Guarantor Subsidiaries (condensed combined
financial data). Separate financial statements and other disclosures concerning
the Guarantor Subsidiaries are not presented because management has determined
that such information would not be material to the holders of the Notes.
8
<PAGE> 10
GUARANTOR SUBSIDIARIES
COMBINED BALANCE SHEETS
As of March 31, 1999 and December 31, 1998
<TABLE>
<CAPTION>
March 31, December 31,
ASSETS 1999 1998
---------- ------------
(Unaudited)
<S> <C> <C>
CURRENT ASSETS:
Cash............................................... $ -- $ (1,412)
Accounts receivable................................ 35,284 30,475
Inventory........................................ 28,319 20,089
Prepaid expenses................................... 770 27
-------- --------
Total current assets......................... 64,373 49,179
Property, plant and equipment, net................. 72,883 72,965
Intangible assets, net............................. 112,596 117,518
-------- --------
Total assets................................. $249,852 $239,662
======== ========
LIABILITIES AND SHAREHOLDERS'
EQUITY
CURRENT LIABILITIES:
Accounts payable................................... $ 8,409 $ 8,157
Accrued expenses................................... 14,898 10,645
Income taxes payable............................... (4,104) --
-------- --------
Total current liabilities.................... 19,203 18,802
Long-term debt:
Intercompany payable............................... 167,786 174,201
-------- --------
Total liabilities............................ 186,989 193,003
-------- --------
Shareholders' Equity............................... 62,863 46,659
-------- --------
Total liabilities and Shareholders' Equity... $249,852 $239,662
======== ========
</TABLE>
9
<PAGE> 11
GUARANTOR SUBSIDIARIES
COMBINED STATEMENTS OF OPERATIONS
For the three months ended March 31, 1998 and 1999
<TABLE>
<CAPTION>
For the Three Months
Ended March 31,
1999 1998
----------- ------------
(Unaudited) (Unaudited)
<S> <C> <C>
REVENUES:
Net sales ....................................... $ 61,907 $ 20,857
Development revenues ............................ -- 2,500
-------- --------
Total revenues ................................ 61,907 23,357
-------- --------
OPERATING COSTS AND EXPENSES:
Cost of sales ................................... 18,690 6,320
Selling, general and administrative ............. 10,830 3,855
Depreciation and Amortization ................... 5,884 1,217
-------- --------
Total operating costs and expenses........ 35,404 11,392
-------- --------
OPERATING INCOME .................................. 26,503 11,965
OTHER (EXPENSES) INCOME
Interest Expense ................................ (69) --
Interest income ................................. -- 1
Other income (expense) .......................... 1 (1)
-------- --------
Income before income taxes ...................... 26,435 11,965
-------- --------
Income tax expense .............................. 10,230 4,630
-------- --------
Net Income ........................................ $ 16,205 $ 7,335
======== ========
</TABLE>
10
<PAGE> 12
GUARANTOR SUBSIDIARIES
COMBINED STATEMENTS OF CASH FLOWS
For the three months ended March 31, 1999 and 1998
<TABLE>
<CAPTION>
For the Three
Months Ended
March 31,
--------------------------
1999 1998
------------ -----------
(Unaudited) (Unaudited)
<S> <C> <C>
NET CASH PROVIDED BY (USED IN)
OPERATING ACTIVITIES ....................... $ 8,776 $ (8,800)
------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment ........ (949) (73,189)
Purchases of intangible assets ............. -- (54,867)
------- ---------
Net cash used in investing activities ... (949) (128,056)
------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Increase (decrease) in inter-company payable (6,415) 137,657
Increase in long-term debt ................. -- (1,751)
------- ---------
Net cash provided by financing activities (6,415) 135,906
------- ---------
Increase (decrease) in cash .................. 1,412 (950)
Cash and cash equivalents,
beginning of the period .................... (1,412) (133)
------- ---------
Cash and cash equivalents,
end of the period .......................... $ -- $ (1,083)
======= =========
</TABLE>
11
<PAGE> 13
PART I - FINANCIAL INFORMATION
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion contains certain forward-looking statements which
reflect management's current views of future events and operations. These
forward-looking statements involve certain significant risks and uncertainties,
and actual results may differ materially from the forward-looking statements.
Some important factors which may cause results to differ include: our
significant leverage and debt service requirements, dependence on our ability to
continue to acquire branded products, dependence on sales of our products,
management of our growth and integration of its acquisitions. Other important
factors that may cause actual results to differ materially from the
forward-looking statements are discussed in "Risk Factors" and other sections of
our prospectus dated June 25, 1998, which is on file with the Securities and
Exchange Commission as part of our Registration Statement on Form S-1. The
Company does not undertake to publicly update or revise any of its
forward-looking statements even if experience or future changes show that the
indicated results or events will not be realized. The following presentation of
management's discussion and analysis of financial condition and results of
operations should be read in conjunction with our unaudited consolidated
financial statements and related notes thereto.
OVERVIEW
We are a vertically integrated pharmaceutical company that
manufactures, markets and sells primarily branded prescription pharmaceutical
products. Through a national sales force of over 200 representatives, we market
our branded pharmaceutical products to general/family practitioners, internal
medicine physicians and hospitals across the country. Our business strategy is
to acquire established branded pharmaceutical products and to increase their
sales by focused marketing and promotion and through product life cycle
management. In pursuing acquisitions, we seek to capitalize on opportunities in
the pharmaceutical industry created by cost containment initiatives and
consolidation among large, global pharmaceutical companies. We also create value
by developing product line extensions for our branded pharmaceutical products
such as new formulations, dosages or new indications. These product line
extensions are attractive for us because they may have market exclusivity or
sales levels that do not attract significant competition. In addition to branded
pharmaceuticals, we also provide contract manufacturing for a number of the
world's leading pharmaceutical and biotechnology companies, including Amgen,
Inc., Warner-Lambert Company, Mallinckrodt Chemical, Genetics Institute, Inc.
and Hoffmann-La Roche Inc.
Our branded pharmaceutical products can be divided into four
therapeutic areas: (i) cardiovascular (including Altace, Thalitone and
Procanbid), (ii) anti-infectives (including Cortisporin, Neosporin and
Coly-Mycin M), (iii) vaccines and biologicals (including Fluogen, Aplisol and
Histoplasmin) and (iv) women's health (including Pitocin and Menest). All of
these products are marketed to general/family practitioners and internal
medicine physicians. Unlike many of our competitors, we have a broad therapeutic
focus that provides us with opportunities to purchase a wide variety of
products, as evidenced by our acquisition of 26 products over the last 18
months, including Altace. In addition, we have well known products in all of our
therapeutic categories that generate high prescription volumes. Our portfolio of
recognized prescription brand names includes, among others, Altace, Neosporin,
Cortisporin, Pitocin, Anusol-HC and Fluogen.
Since December 1994 we have acquired 34 branded pharmaceutical
products, developed three products internally, divested one product and
introduced eight product line extensions. We acquired from Glaxo Wellcome the
Cortisporin product line in March 1997, the Viroptic product line in May 1997
and six additional branded products, including Septra, and exclusive licenses,
free of royalty obligations, for the prescription formulations of Neosporin and
Polysporin in November 1997 (the "Glaxo Acquisition").
In February 1998 we acquired from Warner-Lambert 15 branded
pharmaceutical products, the Parkedale Facility located in Rochester, Michigan
and certain manufacturing contracts for third parties for $127.9 million,
including $2.9 million of assumed liabilities (the "Sterile Products
Acquisition").
12
<PAGE> 14
In June 1998 we acquired the Menest product line from SmithKline
Beecham Corporation ("SmithKline") for $5.0 million.
In June 1998 we launched our new Cortisporin-TC Otic line.
Cortisporin-TC Otic is a product line extension for our Cortisporin Otic
Suspension product.
In August 1998 we received approval by the FDA to reintroduce Fluogen
(influenza virus vaccine, Trivalent, Types A & B), which was acquired as part of
the Sterile Products Acquisition and had been off the market since 1996. Fluogen
is a seasonal product with most of its sales occurring the third and fourth
quarters.
In December 1998 we acquired from HMR for $362.5 million the United
States rights to Altace, an ACE inhibitor, HMR's worldwide rights to Silvadene,
a burn cream, and HMR's worldwide rights to AVC, a vaginal anti- infective
cream (the "Altace Acquisition").
Our strategy is to continue to acquire branded pharmaceutical products
and to create value by leveraging our marketing, manufacturing and product
development capabilities. We expect that our strategy of acquiring branded
pharmaceutical products will increase our revenues as a result of sales of such
products and will increase gross margins. In general, margins are higher on our
branded pharmaceutical products than on our other products, making branded
products attractive to us. As soon as practicable after regulatory requirements
are satisfied and when advantageous, we expect that manufacturing these acquired
pharmaceutical products ourselves will increase our margins because the cost of
producing pharmaceutical products on our own is lower than the cost of having
these products manufactured by third parties. We may also be required to raise
funds through additional borrowings or the issuance of debt or equity securities
in order to finance additional branded product acquisitions and to expand or
remodel our manufacturing facilities.
We manufacture pharmaceutical products for a variety of pharmaceutical
and biotechnology companies under contracts expiring at various times within the
next five years. We intend to enter into additional manufacturing contracts in
cases where we identify contracts that offer significant volumes and attractive
margins. We have not accepted or renewed manufacturing contracts for third
parties where we perceived insignificant volumes or revenues. In accordance with
our focus on branded pharmaceutical products, we expect that, over time, our
contract manufacturing and generic pharmaceutical and companion animal health
product lines will become a smaller percentage of revenues.
The following summarizes approximate net revenues by product categories
(in thousands).
<TABLE>
<CAPTION>
Three Months Ended March 31
1999 1998
---- ----
<S> <C> <C>
Branded pharmaceuticals $ 50,939 $ 17,570
Contract manufacturing 8,063 4,518
Other 1,000 2,889
-------- ---------
Total $ 60,002 $ 24,977
======== =========
</TABLE>
13
<PAGE> 15
RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 1999 AND 1998
Revenues
Net revenues increased $35.0 million, or 140.2%, to $60.0 million in
1999 from $25.0 million in 1998. The increase in revenues is primarily
attributable to the Altace Acquisition in December, and the Sterile Products
Acquisition in March of 1998.
Net sales from branded pharmaceuticals increased $33.3 million in 1999
or 189.9% to $50.9 million in 1999 from $17.6 million in 1998. The increase in
revenues from branded pharmaceuticals is primarily attributable to the Altace
Acquisition in December of 1998, and the Sterile Products Acquisition in March
of 1998. The Altace Acquisition contributed $23.2 million in net sales during
the quarter. The revenue from the branded products purchased as part of the
Sterile Products Acquisition in March 1998 increased $6.6 million or 100.0% to
$13.2 million in 1999 from $6.6 million in 1998.
Revenues from contract manufacturing increased $3.5 million, or 78.5%,
to $8.1 million in 1999 from $4.5 million in 1998. This increase is primarily
due to a full quarter of contract manufacturing revenue related to the Sterile
Products Acquisition, versus only one-month of contribution in 1998.
We recognized no development revenues in the first quarter of 1999. In
1998 we recognized $2.5 million in development revenues as a result of the Food
and Drug Administration ("FDA") approval and our validation of the process of
one additional ANDA pursuant to an agreement with Mallinckrodt Chemical.
Currently, we have no ongoing agreements that would result in future development
revenue recognition.
Gross Profit
Total gross profit increased $26.6 million or 150.9% to $44.2 million
in 1999 from $17.6 million in 1998. The increase in gross profit is primarily
attributable to the increase in gross profit from branded pharmaceutical
products of $27.5 million offset by a decrease in gross profit from contract
development activities.
The gross profit from branded pharmaceutical products increased $27.5
million or 181.1% to $42.7 million in 1999 from $15.2 million in 1998. The
increase is primarily the result of the Altace Acquisition and the branded
products purchased as part of the Sterile Products Acquisition.
The gross profit from contract manufacturing increased $1.2 million or
298.5% to $794,000 in 1999 from ($400,000) in 1998. The increase is attributable
to a full quarter of operations from the contract manufacturing business
acquired as part of the Sterile Products Acquisition, and greater utilization of
our manufacturing facilities during the quarter.
Gross profit associated with contract development revenue, generic
pharmaceutical sales, and companion animal health sales decreased by $2.2
million or 76.6% to $656,000 in 1999 from $2.8 million in 1998. The decrease is
primarily because we had no development revenues during the quarter; this was
partially offset by an increase in gross profit contribution from generic
pharmaceutical products.
Operating Costs and Expenses
Total operating costs and expenses increased $21.1 million, or 137.8%,
to $36.3 million in 1999 from $15.3 million in 1998. The increase was due to
increases in the costs associated with our growth, particularly the Sterile
Products Acquisition and the Altace Acquisition.
Cost of sales increased $8.4 million, or 114.7%, to $15.8 million in
1999 from $7.4 million in 1998. The increase was due primarily to the costs
associated with the newly acquired branded product lines.
Selling, general and administrative expenses increased $7.5 million, or
109.0%, to $14.3 million in 1999 from $6.8 million in 1998. As a percentage of
net sales, selling, general and administrative expenses decreased from 30.6% to
23.8% due to the increase in sales volume without a corresponding increase in
fixed costs. This increase was primarily attributable to the hiring of
additional sales representatives during the second half of 1998 and first part
of 1999; as well as other personnel costs, marketing, and sampling costs
associated with the new branded product lines.
Depreciation and amortization expense increased $5.2 million, or
473.0%, to $6.3 million in 1999 from $1.1 million in 1998. This increase was
primarily attributable to the depreciation and amortization of the fixed assets
and intangibles assets acquired the Sterile Products Acquisition in March 1998
and the Altace Acquisition in December 1998.
Operating Income
Operating income increased $14.0 million, or 144.2%, to $23.7 million
in 1999 from $9.7 million in 1998. This increase was primarily due to increased
revenues from the acquisition of branded products offset by increased expenses
described above. As a percentage of net revenues, operating income increased to
39.4% in 1999 from 38.8% in 1998.
Interest Expense
Interest expense increased $10.0 million, or 370.6%, to $12.7 million
in 1999 from $2.7 million in 1998, as a result of additional term loans used to
finance, in part, the Sterile Products Acquisition in February 1998 for $125.0
million, and the Altace Acquisition in December 1998 for $362.5 million.
14
<PAGE> 16
Income Tax Expense
The effective tax rate in 1999 of 38.5% and 1998 of 37.8% was higher
than the federal statutory rate of 35% primarily due to state income taxes.
Extraordinary Item
During the first quarter of 1999, we repaid $75.0 million of Senior
Subordinated Notes prior to maturity. The early repayment of the notes caused us
to recognize an extraordinary loss of $705,000, net of related tax benefits of
$445,000, from the write-off of certain deferred financing costs.
Net Income
Due to the factors set forth above, net income increased $1.9 million,
or 47.1%, to $6.0 million in 1999 from $4.1 million in 1998.
LIQUIDITY AND CAPITAL RESOURCES
General
Our liquidity requirements arise from debt service, working capital
requirements and funding of acquisitions of branded products.
As of March 31, 1999 we have available $98.2 million under a
revolving credit facility, which allows for total borrowing of up to $100.0
million.
We generated net cash from operations of $5.5 million for the three
months ended March 31, 1999. Our net cash provided from operations was primarily
the result of $6.0 million in net income, depreciation and amortization of $6.3
million, a non-cash extraordinary charge of $1.2 million before income tax
benefit, and an increase in accrued expenses of $4.5 million. Additionally, we
decreased other assets by $1.1 million and recorded $603,000 of non-cash
amortization of loan fees. Our cash flow from operations was also impacted by an
increase in receivables, inventory, and prepaid assets of $3.6 million, $10.0
million and $995,000, respectively.
Cash flows used in investing activities was $1.7 million due to the
purchases of property and equipment.
Net cash used in financing activities was $2.5 million. Financing
activities provided $155.0 million comprised of $150.0 million in proceeds from
senior subordinated notes, and $5.0 million in proceeds from the revolving
credit facility. These amounts were offset by repayments of the $75.0 million
senior subordinated notes, $53.8 million relating to the term loans, and
$22.2 million on the revolving credit facility. Additionally, we paid $6.5
million of loan closing fees related to the term loans and the senior
subordinated notes.
As of March 31, 1999 we have outstanding approximately $530.0 million
of long-term debt (including current portion), and $1.8 million in borrowings
under our revolving credit facility. Of these amounts, approximately $373.0
million were at variable rates based on LIBOR and the remainder at fixed rates.
We have entered into $125.0 million of interest rate hedging transactions with a
commercial bank to exchange its variable LIBOR for a fixed rate of interest. We
do not believe our exposure to changes in interest rates under our remaining
variable rate agreements will have a material effect on our financial condition
or results of operations. Certain financing arrangements require us to maintain
certain minimum net worth, debt to equity, cash flow and current ratio
requirements. As of March 31, 1999 we were in compliance with these covenants.
We believe that existing credit facilities and cash expected to be
generated from operations are sufficient to finance our current operations and
working capital requirements. However, in the event we make significant future
15
<PAGE> 17
acquisitions, it may be required to raise funds through additional borrowings or
the issuance of additional debt or equity securities. At present, we are
actively pursuing the acquisition of additional branded pharmaceutical products
that may require the use of substantial capital resources. There are, however,
no present agreements or commitments with respect to any such acquisitions.
Capital Expenditures
Capital expenditures, including capital lease obligations, were $1.7
million and $73.6 million for the three months ended March 31, 1999 and 1998.
The principal capital expenditures included property and equipment purchases and
building improvements. We anticipate total capital expenditures in 1999 to be
approximately $6.0 million primarily to fund additional equipment purchases and
building improvements. In addition, we expect to increase our capital
expenditures over the next few years as a part of our acquisition and growth
strategy.
Year 2000 Compliance
We have conducted an evaluation of our IT and non-IT computer systems
with respect to the "Year 2000" issue. This issue arises because many electronic
systems use two digits rather than four to determine dates. This could cause
information technology systems such as software applications, hardware, network
systems and embedded systems to misread important dates beginning in the year
2000, which could cause system failures and disruption of operations.
We have completed a Year 2000 readiness assessment of our business
critical IT and non-IT systems. As a result of the assessment, we are in the
process of developing and implementing corrective action plans designed to
address Year 2000 issues. These plans, which include modification, upgrade and
replacement of our critical administrative, production and research and
development computer systems to make them Year 2000 ready. Implementation of
corrective action plans has begun, and we expect to have our critical systems
Year 2000 ready by June 1999.
Because our operations depend on the uninterrupted flow of materials
and services from our suppliers, we have requested and have been receiving and
analyzing information from our suppliers with regard to their progress toward
Year 2000 readiness. We intend to continue to monitor the progress of our key
suppliers toward Year 2000 readiness.
We estimate that we will spend, in total, between $1.0 million and $1.5
million to become Year 2000 ready. The majority of this spending will constitute
replacement costs of non-compliant IT systems and reprogramming existing
systems. It is possible that the actual cost of our Year 2000 readiness effort
could exceed these estimates.
Although we have a process in place to assess Year 2000 readiness on
the part of our suppliers, we consider the most reasonably likely worst case
scenario is that one or more of our suppliers might encounter a Year 2000
problem and be unable to supply materials. If this occurs and we could not
obtain the same materials from another vendor, production could be interrupted,
which could result in lost sales and profits. In addition, while we are taking
action to correct deficiencies in our own systems, it is possible that one or
more of our facilities or critical business systems might not achieve Year 2000
readiness as anticipated. This could also result in disruption of operations and
lost sales and profits.
We do not manufacture any products that are subject to Year 2000 risks.
Contingency plans are being or will be developed to avoid or mitigate the risks
that either key suppliers or we might not achieve Year 2000 readiness in time to
avoid disruption of our operations.
16
<PAGE> 18
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Many distributors, marketers and manufacturers of anorexigenic drugs
have been subject to claims relating to the use of these drugs. We are a
defendant in 67 lawsuits which claim damages for personal injury arising from
our production of the anorexigenic drug phentermine under contract for SKB.
Generally, the lawsuits allege that the defendants (1) misled users of the
products with respect to the dangers associated with them, (2) failed to
adequately test the products, and (3) knew or should have known about the
negative effects of the drugs, and should have informed the public about the
risks of such negative effects. The actions generally have been brought by
individuals in their own right and have been filed in various state and federal
jurisdictions throughout the United States. They seek, among other things,
compensatory and punitive damages and/or court-supervised medical monitoring of
persons who have ingested the product. We expect to be named in additional
lawsuits related to production of this anorexigenic drug.
While we cannot predict the outcome of these suits, we believe that the
claims against us are without merit and intend to vigorously pursue all defenses
available to us. We are being indemnified in all of these suits by SKB for which
we manufacture the anorexigenic product, provided that neither the lawsuits nor
the associated liabilities are based upon our independent negligence or
intentional acts, and intend to submit a claim for all unreimbursed costs to its
product liability insurance carrier. However, in the event that SKB is unable to
satisfy or fulfill its obligations under the indemnity, we would have to defend
the lawsuit and be responsible for damages, if any, which are awarded against us
or for amounts in excess of our product liability coverage.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
On March 3, 1999, we issued $150 million of 10 3/4% Senior Subordinated
Notes due 2009. Net proceeds of approximately $144 million were used to repay
outstanding indebtedness under the Senior Credit Facility ($69 million) and the
Seller Note ($75 million). The debt is guaranteed by our wholly-owned
subsidiaries Monarch Pharmaceuticals, Inc., Parkedale Pharmaceuticals, Inc. and
King Pharmaceuticals of Nevada, Inc.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit No. Description
(27.1) Financial Data Schedule (For SEC Use Only)
17
<PAGE> 19
(b) Reports on Form 8-K
(b) During the quarter ended March 31, 1999, King filed a Current Report on
Form 8-K, in response to Item 2 of that Form, dated January 6, 1999,
related to the December 22, 1998 acquisition of three branded
pharmaceutical products from Hoechst Marion Roussel. We filed an amended
Current Report on Form 8-K/A on February 9, 1999 which included the
following financial statements:
(1) Special Purpose Financial Statements of Businesses Acquired.
ALTACE PRODUCT LINE OF HOECHST MARION ROUSSEL, INC. AND
HOECHST MARION ROUSSEL DEUTSCHLAND GMBH
Independent Auditors' Report
Special Purpose Statement of Product Contribution for the
nine months ended September 30, 1998 and the years
ended December 31, 1997 and 1996
Notes to Special Purpose Statement of Product Contribution
SILVADENE PRODUCT LINE OF HOECHST MARION ROUSSEL, INC.
Independent Auditors' Report
Special Purpose Statement of Product Contribution for the
nine months ended September 30, 1998 and the years
ended December 31, 1997 and 1996
Notes to Special Purpose Statement of Product Contribution
AVC PRODUCT LINE OF HOECHST MARION ROUSSEL, INC.
Independent Auditors' Report
Special Purpose Statement of Product Contribution for the
nine months ended September 30, 1998 and the years
ended December 31, 1997 and 1996
Notes to Special Purpose Statement of Product Contribution
(2) Unaudited Pro Forma Consolidated Financial Information.
Unaudited Pro Forma Consolidated Financial Statements
King Pharmaceuticals, Inc. Unaudited Pro Forma Consolidated
Balance Sheet as of September 30, 1998
Notes to Unaudited Pro Forma Consolidated Balance Sheet
King Pharmaceuticals, Inc. Pro Forma Consolidated Statement of
Operations for the Twelve Months Ended December 31, 1997
King Pharmaceuticals, Inc. Pro Forma Consolidated Statement of
Operations for the Nine Months Ended September 30, 1998
Notes To Unaudited Pro Forma Consolidated Statements of
Operations
18
<PAGE> 20
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
King Pharmaceuticals, Inc.
Date: May 14, 1999 By: /s/ John M. Gregory
------------------- -----------------------------------------
John M. Gregory
Chairman and Chief Executive Officer
Date: May 14, 1999 By: /s/ Brian G. Shrader
----------------- -----------------------------------------
Brian G. Shrader
Chief Financial Officer
19
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 2,484
<SECURITIES> 0
<RECEIVABLES> 37,922
<ALLOWANCES> (1,369)
<INVENTORY> 36,553
<CURRENT-ASSETS> 90,565
<PP&E> 102,922
<DEPRECIATION> (8,609)
<TOTAL-ASSETS> 682,082
<CURRENT-LIABILITIES> 46,593
<BONDS> 150,000
0
0
<COMMON> 0
<OTHER-SE> 107,433
<TOTAL-LIABILITY-AND-EQUITY> 682,082
<SALES> 60,002
<TOTAL-REVENUES> 60,002
<CGS> 15,810
<TOTAL-COSTS> 36,343
<OTHER-EXPENSES> (88)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 12,719
<INCOME-PRETAX> 10,898
<INCOME-TAX> 4,200
<INCOME-CONTINUING> 5,993
<DISCONTINUED> 0
<EXTRAORDINARY> (705)
<CHANGES> 0
<NET-INCOME> 5,993
<EPS-PRIMARY> .19
<EPS-DILUTED> .19
</TABLE>
